Satoshi Taira
Presidente presso Titan, Inc. (Japan)
Profilo
Satoshi Taira is currently the President & Representative Director at Titan, Inc. (Japan) and Tella Pharma, Inc. He was previously the President & Representative Director at tella, Inc. from 2019 to 2021.
Posizioni attive di Satoshi Taira
| Società | Posizione | Inizio |
|---|---|---|
Titan, Inc. (Japan)
 Titan, Inc. (Japan) Data Processing ServicesTechnology Services Titan, Inc. provides imaging solutions and clinical trial support services. The company was founded on May 2, 2013 and is headquartered in Tokyo, Japan. | Presidente | - |
Tella Pharma, Inc.
 Tella Pharma, Inc. Medical SpecialtiesHealth Technology Founded in 2014, Tella Pharma, Inc. is a Japanese company that manufactures clinical test equipment. The company is based in Tokyo, Japan. | Presidente | 01/05/2019 |
Precedenti posizioni note di Satoshi Taira
| Società | Posizione | Fine |
|---|---|---|
| TELLA, INC. | Presidente | 20/07/2021 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 3 |
|---|---|
Titan, Inc. (Japan)
Titan, Inc. (Japan) Data Processing ServicesTechnology Services Titan, Inc. provides imaging solutions and clinical trial support services. The company was founded on May 2, 2013 and is headquartered in Tokyo, Japan. | Technology Services |
Tella Pharma, Inc.
Tella Pharma, Inc. Medical SpecialtiesHealth Technology Founded in 2014, Tella Pharma, Inc. is a Japanese company that manufactures clinical test equipment. The company is based in Tokyo, Japan. | Health Technology |
tella, Inc.
 tella, Inc. BiotechnologyHealth Technology tella, Inc. engages in research and development of dendritic cell (DC) vaccine therapy. It operates through the following segments: Cell Medicine, Medical Support, and Pharmaceuticals. The Cell Medicine segment provides cancer treatment technology and know-hows centered on dendritic cell vaccine therapy. The Medical Support segment manages contact research organization (CRO) business and offers genetic testing services. The Pharmaceuticals segment deals with the development of dendritic cell vaccine as a cancer treatment. The company was founded by Yuichiro Yazaki on June 24, 2004 and is headquartered in Tokyo, Japan. | Health Technology |
- Borsa valori
- Insiders
- Satoshi Taira